Liberty Health Sciences Inc.
| Company Name | Liberty Health Sciences Inc. |
| Stock Symbol | LHSIF |
| Class Period | June 28, 2018 to December 03, 2018 |
| Lead Plaintiff Motion Deadline | March 08, 2019 |
In September 2018, Liberty sold its stake in Aphria Inc. (“Aphria”). On December 3, 2018, Quintessential Capital Management and Hindenburg Research issued a report entitled “Aphria: A Shell Game with a Cannabis Business on the Side,” claiming that Aphria was part of a scheme orchestrated by a network of insiders to divert funds away from shareholders and into their own pockets.
On this news, Liberty’s stock price fell $0.36 per share, or nearly 34%, over the next two trading days to close at $0.70 on December 4, 2018, thereby injuring investors.
The complaint filed in this class action alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) Liberty, in conjunction with Aphria, was involved in a scheme whereby numerous fraudulent acquisitions and transactions were made to provide undue benefits to both companies’ insiders; and (ii) as a result, Liberty’s public statements were materially false and misleading at all relevant times.
Submit Your Information
If you suffered a loss on your Liberty Health Sciences Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.